The concept that IL-1 possessed these seemingly unrelated properties was diagramed in 1984 (4 and Fig. 1), without the benefit of recombinant IL-1 to validate the concept. The scientific community, being skeptical of the concept that a single small protein could have such a spectrum of activities, demanded confirmation with recombinant IL-1. Following the isolation of the cDNA for IL-1α 5 and IL-1β 6 in 1984, studies using the recombinant forms confirmed the growing list of inflammatory properties of IL-1. Indeed, recombinant Ivacaftor supplier IL-1α or IL-1β provided ample evidence for the broad role of IL-1 in health as well as disease (Fig. 2) The availability of recombinant

forms also allowed for the development specific assays such as radioimmunoassays and later ELISAs. These assays changed how many viewed cytokines since the immunoassays liberated the investigator

from the non-specific bioassays that had dominated and confused the field for 20 years. The specific assays now told another story and that was the ability to follow a disease process or a therapy in terms of changes in cytokine levels. However, the greatest contributions of the recombinant forms of IL-1 were the responses they triggered upon administration to humans. Cancer patients undergoing bone marrow transplantation were injected with either IL-1α or IL-1β to stimulate hematopoiesis Table 1 summarizes the human responses observed, and physiologic responses such as fever following injection of 10 ng/Kg IL-1α or IL-1β match those observed using CX-4945 solubility dmso purified human leukocytic pyrogen injected into rabbits in 1977 2. Next in the history of IL-1 was the identification of the naturally occurring and specific inhibitor of IL-1 activity 7–9, later found to be the IL-1 receptor antagonist (IL-1Ra). IL-1Ra was developed into a therapeutic (anakinra) and tested in humans. Anakinra is a pure receptor antagonist binding tightly to the type I IL-1 receptor (IL-1RI) and preventing selleck kinase inhibitor activation of this receptor by either IL-1β or IL-1α. Approved for treating patients

with rheumatoid arthritis, the use of anakinra validated the importance of IL-1 in a broad spectrum of inflammatory diseases. More recently, soluble receptors for IL-1 (rilonacept) and human mAbs to IL-1β (canakinumab and Xoma 052) have been used to neutralize IL-1β specifically. In most reports, summarized in Table 2, there is a dramatic, rapid and sustained improvement in patients following a reduction in IL-1β activity. Thus, from clinical studies using IL-1β neutralization, one concludes that this cytokine should be considered a gatekeeper of inflammation. The term was first used to describe a rare disease characterized by recurrent bouts of fever and systemic inflammation due to a mutation in the coding region of the p55 TNF-receptor 10. The disease was traditionally called Familial Hibernian Fever but is now called TNF-receptor-associated periodic syndrome or TRAPS.